Misclassification of Pulmonary Hypertension With Current Hemodynamic Criteria
- PMID: 39209062
- DOI: 10.1016/j.chest.2024.05.053
Misclassification of Pulmonary Hypertension With Current Hemodynamic Criteria
Conflict of interest statement
Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: A. S. has received research funding from Abbott, Edwards Lifesciences, Vifor, Pfizer, Bayer, General Prognostics, Story Health, Acorai, Boston Scientific, and Impulse Dynamics; is on the steering committees of Abbott, Boston Scientific, Biotronik, Story Health, RIVUS, Bayer, and General Prognostics; and is a consultant for Abbott, Boston Scientific, Edwards Lifesciences, Impulse Dynamics, Acorai, Story Health, General Prognostics, and Bayer. None declared (M. G., K. M., H. S., E. V., M. B., T. A. B., K. B., A. B., A. G., T. F., M. F., J. T. H., E. M., O. J., L. K., P. M., M. R.).
LinkOut - more resources
Full Text Sources